| (Values in U.S. Thousands) | Feb, 2025 | Feb, 2024 | Feb, 2023 | Dec, 2025 | Dec, 2025 |
| Sales | 118 | 123 | 170 | 0 | 0 |
| Sales Growth | -3.73% | -27.72% | unch | unch | unch |
| Net Income | -216 | -1,398 | -3,078 | 0 | 0 |
| Net Income Growth | +84.56% | +54.60% | unch | unch | unch |
Optimind Pharma Corp. (OMND.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Optimind Pharma Corp, through its clinic, specializes in prescribing medical cannabis and other alternative treatments for various medical ailments. It offers psychedelic-like therapies at its clinic, helping people suffering from PTSD, anxiety, depression, and other mental illnesses and disabilities by providing ketamine-assisted treatment and other psychedelic-enhanced psychotherapy modalities. The company is also partnered with developers of psilocybin-associated treatments and products to further expand its treatment and program offerings.
Fiscal Year End Date: 02/28